Susan Samson, MD, PhD, of Baylor College of Medicine talks about the recently approved Mycapssa (octreotide) capsules as long-term maintenance therapy for people with acromegaly.

Mycapssa is the only oral form of octreotide, a somatostatin analog, approved by the US Food and Drug Administration (FDA) to treat acromegaly.

Acromegaly is a rare endocrine disorder usually caused by a benign pituitary tumor and is characterized by excess production of growth hormone and insulin-like growth factor-1 hormone.

As Dr. Samson explains in this interview, the approval was largely based on the pivotal phase 3 CHIASMA OPTIMAL clinical trial showing Mycapssa to be superior to placebo in the randomized, double-blind, placebo-controlled, nine-month study.

The most common adverse events observed with Mycapssa were: cholelithiasis and complications of cholelithiasis; hyperglycemia and hypoglycemia; thyroid function abnormalities; cardiac function abnormalities; and decreased vitamin B12 levels and abnormal Schilling’s tests.

0 Comments

Up next

Autoplay

Dulaglutide Webinar - The Long-awaited New Agent to treat Type 2 diabetes

1 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

New Oral Octreotide Approved to Treat Acromegaly

Up next

Language